56 results about "Carbapenem" patented technology

The invention discloses an antibacterial peptide based on D-type amino acid and application of the antibacterial peptide, and the antibacterial peptide is characterized in that the amino acid sequence is w-r-r-w-r-r-w-w-r-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dLys-dArg). The antibacterial peptide can be synthesized through an Fmoc solid-phase chemical method, the synthesis difficulty is low, and the in-vivo antibacterial activity is good. The antibacterial peptide especially has broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus, is low in hemolytic toxicity, can reach half or more of cell survival rate under medium and low concentration, almost has no toxic effect on cells, and can be used for preparing the antibacterial peptide with a broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus. The stability is good, the operability is high, and the cost is low.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention designs a carbapenem drug-resistant gene nucleic acid fluorescent PCR method detection kit and application thereof, the kit uses Taqman fluorescent probe multiple amplification technology to detect carbapenem drug-resistant genes, the kit comprises a nucleic acid reaction liquid Mix1 and a nucleic acid reaction liquid Mix2, the nucleic acid reaction liquid Mix1 is used for detecting drug-resistant genes IMP, NDM and OXA48, the nucleic acid reaction liquid Mix2 is used for detecting drug-resistant genes IMP, NDM and OXA48, and the nucleic acid reaction liquid Mix2 is used for detecting drug-resistant genes IMP, NDM and OXA48. The nucleic acid reaction liquid Mix2 is used for detecting drug resistance genes VIM, KPC and OXA23. The method is high in detection specificity, and the detection result is visual and easy to interpret. Clinical doctors are assisted to judge respiratory tract pathogen infection more comprehensively and more accurately. The kit covers six carbapenem drug resistance genes, is more comprehensive and accurate in detection, and is high in specificity and sensitivity. Meanwhile, multiple sample types can be detected, a sputum sample, an excrement sample and a rectum swab sample are detected through paramagnetic particle extraction, and pure bacterial colonies are directly detected without extraction.

The present application belongs to the technical field of artificial intelligence assisted drug screening, and particularly relates to a method for screening active molecules against carbapenem-resistant enterobacteriaceae based on a LightGBM algorithm, a medium and an apparatus. The method constructs a LightGBM integrated learning framework, fuses ADME rules optimized for the outer membrane barrier characteristics of gram-negative bacteria and multi-target molecule docking verification, effectively solves the problem of data imbalance caused by the scarcity of active samples and the huge compound library, and significantly improves the hit rate of screening. The present application also provides a computer readable storage medium and an electronic device. By storing and executing the above program, the present application can quickly and standardizedly identify anti-CRE candidate molecules from a large number of compounds, greatly reducing the computing power cost and time cycle of new drug research and development. The present application is designed to overcome the bottleneck of gram-negative bacterial outer membrane permeation, and provides an efficient, accurate and intelligent screening tool for combating CRE super-bacterial infections.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

This invention relates to the synthesis of compounds that can be used to treat bacterial infections in combination with other antibacterial agents, and more specifically in combination with a class of antibacterial agents known as carbapenems. The compounds resulting from the novel methods of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

The present application relates to a kind of targeting bacterial UDP-N-acetylglucosamine enolpyruvate transaminase antibacterial compound and its application, the antibacterial compound is S-(4-chlorobenzyl) chloro isothiourea, its chemical structure is as shown in formula I: I;Or its pharmaceutically acceptable salt, stereoisomer, solvate, crystal form, isotopically labeled or prodrug.The antibacterial compound of the present application can effectively inhibit the growth of klebsiella pneumoniae, including carbapenem-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae;It also has good bacteriostatic effect on escherichia coli and pseudomonas aeruginosa;It is expected to be applied to the clinical treatment of infection caused by drug-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae and other pathogenic bacteria, and has important clinical significance and social benefits.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The invention discloses a carbapenem drug resistance marker screening method and system based on a cross-species compressed Debrueine diagram and a medium. The method comprises the following steps: starting from whole genome sequencing data of gram-negative bacteria belonging to different species and carbapenem drug phenotypes of the gram-negative bacteria, constructing a compressed Debrueine graph based on cross-species joint data, and taking existence / deletion of nodes in the graph as unified genetic variation characteristics. Performing correlation analysis on the nodes and the drug resistance phenotypes by using a linear hybrid model to obtain a candidate node set related to the phenotypes; k-mer is extracted based on the candidate node sequence, and secondary statistical screening is completed in combination with chi-square test and mutual information; and finally determining a group of carbapenem drug-resistant genetic markers which can be applicable across species through a hierarchical feature selection strategy of random forest and XGBoost. Efficient dimension reduction of large-scale cross-species genome data, cross-species consistent variation representation and high-interpretability marker screening are achieved.

This invention discloses a primer and probe set, kit, and method for detecting carbapenem resistance genes using point-of-care testing (POCT), belonging to the field of gene detection technology. The carbapenem resistance genes include: NDM, KPC, VIM, IMP, OXA, and GES; the primers and probes for the NDM gene include: SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3; the primers and probes for the KPC gene include: SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6; the primers and probes for the VIM gene include: SEQ ID NO.7, SEQ ID NO.8, and SEQ ID NO.9; the primers and probes for the IMP gene include: SEQ ID NO.10, SEQ ID NO.11, and SEQ ID NO.12; the primers and probes for the OXA gene include: SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, SEQ ID NO.20, and SEQ ID NO.21; and the primers and probes for the GES gene include: SEQ ID NO.22, SEQ ID NO.23, and SEQ ID NO.24. The primer and probe set, kit, and method of this invention can be used to detect carbapenem resistance genes NDM (75 subtypes), KPC (232 subtypes), VIM (90 subtypes), IMP (101 subtypes), GES (64 subtypes), and OXA-48, 23, 51, and 213 groups in a single detection tube. They have the advantages of short detection time, simple operation, wide coverage, good specificity, and prevention of contamination.

The invention relates to the technical field of biological detection, in particular to a primer probe composition for detecting a KPC type carbapenem drug-resistant gene and application of the primer probe composition. In order to solve the technical problems of long detection time, missing detection of partial subtypes, existence of cross reaction, insufficient sensitivity and the like in KPC gene detection in the prior art, the invention discloses a primer probe composition for detecting KPC type carbapenem drug resistance genes, the primer probe composition comprises a primer pair, the primer pair comprises a forward primer and a reverse primer, and the forward primer and the reverse primer are used for detecting the KPC type carbapenem drug resistance genes. The nucleotide sequence of a forward primer is shown as SEQ ID NO: 1, and the nucleotide sequence of a reverse primer is shown as SEQ ID NO: 2; the nucleotide sequence of the probe is as shown in SEQ ID NO: 3. Meanwhile, a reaction system is optimized, a matched detection kit and a standardized detection process are constructed, detection can be completed within 45 minutes, and cross reaction with carbapenemase genes such as NDM, VIM, IMP and OXA does not exist.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

The application discloses a D-type amino acid-based antibacterial peptide and application thereof, and has the amino acid sequence of w-r-r-w-r-r-w-w-r-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dLys-dArg). The antibacterial peptide can be synthesized by Fmoc solid-phase chemical synthesis, has low synthesis difficulty, and has good in-vivo antibacterial activity. The antibacterial peptide has broad-spectrum killing activity on carbapenem-resistant pseudomonas aeruginosa, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, methicillin-resistant staphylococcus aureus and staphylococcus aureus, has low hemolytic toxicity, can reach more than half of the cell survival rate at a medium or low concentration, has almost no toxic effect on cells, has good stability, has strong operability, and is low in cost.

The invention discloses an antibacterial 10 peptide, which is characterized in that the sequence of the antibacterial 10 peptide is w-k-r-w-r-r-r-w-w-r-r (dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), and all amino acids are D-type amino acids. The antibacterial peptide provided by the invention has good antibacterial activity on various pathogenic bacteria, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and relatively good in-vivo antibacterial activity. The antibacterial peptide has broad-spectrum killing activity on multidrug-resistant acinetobacter baumannii, carbapenem-resistant pseudomonas aeruginosa and standard strains of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, methicillin-resistant staphylococcus aureus and staphylococcus aureus, and is low in hemolytic toxicity and high in killing activity. Under medium and low concentration (2 microgram / mL to 32 microgram / mL), the cell survival rate can reach more than half, and the cell culture medium has no toxic effect on cells, and is good in stability, strong in operability and low in cost.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

This invention discloses the application of cinnamaldehyde as a potentiator for β-lactam antibiotics in inhibiting carbapenem-resistant Escherichia coli (CREC). The study confirms that cinnamaldehyde not only inhibits the growth of drug-resistant E. coli but also enhances the antibacterial activity of β-lactam antibiotics, effectively reducing the minimum inhibitory concentration (MIC) of meropenem and cefqinome against drug-resistant E. coli. Further research shows that high concentrations of cinnamaldehyde inhibit New Delhi metallo-β-lactamase-5 (NDM-5) enzyme. This discovery provides a new strategy for addressing the resistance of CREC to β-lactam antibiotics.

This invention relates to an antimicrobial peptide and its applications. The amino acid sequence of the antimicrobial peptide is at least one of the sequences shown in SEQ ID No. 1 to SEQ ID No. 8. The antimicrobial peptide exhibits excellent broad-spectrum antimicrobial activity, for example, against Acinetobacter spp. (…). Acinetobacter ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ) and Bacillus spp. ( Bacillus This bacterium possesses antibacterial activity. Against the backdrop of increasingly severe global bacterial resistance and the gradual ineffectiveness of traditional antibiotics against multidrug-resistant bacteria, this provides a new treatment option for carbapenem-resistant bacteria such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Bacillus subtilis, which pose a significant threat to public health, and offers new possibilities for solving the clinical dilemma of "no available drugs."

The invention relates to the technical field of medicines, in particular to application of combination of meropenem or aztreonam and paromomycin sulfate in preparation of antibacterial drugs. The experimental result of the in vitro combination effect shows that when meropenem or aztreonam is combined with paromomycin sulfate, the meropenem or aztreonam has a remarkable synergistic effect on carbapenem-resistant klebsiella pneumoniae, and paromomycin sulfate can reduce the bacteriostatic concentration of meropenem or aztreonam, so that the meropenem or aztreonam can be used for preparing the medicine for treating the carbapenem-resistant klebsiella pneumoniae. Therefore, the paromomycin sulfate can be used for improving the inhibition effect of meropenem or aztreonam on carbapenem-resistant klebsiella pneumoniae.

The application discloses a kind of pharmaceutical composition, and the pharmaceutical active ingredient of its drug includes desoximycin and meropenem.The composition can synergistically and efficiently inhibit klebsiella pneumoniae, especially KPC-2 positive carbapenem-resistant klebsiella pneumoniae and NDM-5 positive carbapenem-resistant klebsiella pneumoniae, with application prospect.

The invention discloses a specific primer group for simultaneously detecting six carbapenem drug-resistant genes as well as a related method and application of the specific primer group, and the specific primer group is designed aiming at the carbapenem drug-resistant genes. A detection technology system capable of simultaneously detecting the six carbapenem drug-resistant genes is established through a multiplex PCR technology, and the method is rapid and accurate in detection, relatively high in sensitivity, high in automation degree and low in cost, has obvious advantages, can better meet the requirements of rapid and accurate clinical diagnosis, and has good application prospects. The important theoretical innovation significance and clinical transformation potential are realized.

This invention relates to a screening method and application of traditional Chinese medicine inhibitors against carbapenem-resistant Klebsiella pneumoniae, belonging to the field of biomedical technology. Based on a high-throughput screening system for carbapenem-resistant Klebsiella pneumoniae inhibitors constructed using a fluorescent probe for carbapenemase activity detection, the invention successfully screened out mulberry bark as a carbapenemase inhibitor, sanghorn ketone G. When used in combination with meropenem, this inhibitor significantly inhibits the metabolism of meropenem by carbapenem-resistant Klebsiella pneumoniae, greatly enhancing the inhibitory efficiency of meropenem against the strain, providing a highly effective and valuable combination therapy for clinical treatment of carbapenem-resistant Klebsiella pneumoniae infection.

The application discloses synthesis of a novel Schiff base gold (III) compound and antibacterial application thereof, and belongs to the technical field of medicine preparation; gold sodium aurothiomalate has significant antibacterial activity, but the Au-S bond thereof is easily broken by intracellular reducing thiol, and the gold sodium aurothiomalate is metabolized before reaching a target point to produce toxic side effects; based on the gold sodium aurothiomalate, developing a gold compound with stronger stability is one of strategies for overcoming drug-resistant bacteria; the Schiff base itself has antibacterial activity, and after being combined with gold (III) ions, the Schiff base can stabilize gold atoms and improve the activity of the gold atoms; in vitro antibacterial activity shows that Au6 and Au13 have significant antibacterial advantages on carbapenem and polymyxin-resistant Klebsiella pneumoniae, the minimum inhibitory concentration (MIC) is 10 micromoles, and the antibacterial activity is at least 16 times higher than that of the gold sodium aurothiomalate; in vivo antibacterial activity experiments prove that Au6 and Au13 can reduce mouse skin infection and promote wound healing, and can prolong the survival time of abdominal infection mice, and have important practical application value.

This invention discloses the use of a bacterial membrane dCACHE-type chemokine receptor protein family as a target in the preparation or screening of drugs against multidrug-resistant bacteria, belonging to the field of biomedical technology. This invention reveals and verifies for the first time the core regulatory mechanism of the dCACHE-type chemokine receptor protein family in the bacterial infection process: these proteins are key membrane surface receptors mediating bacterial chemotaxis towards macrophages; their loss of function can directly block bacterial chemotactic movement and significantly reduce pathogenicity. This invention, by targeting the conserved ligand binding interface, successfully inhibited the infectivity of drug-resistant pathogens such as *Yersinia pseudotuberculosis*, carbapenem-resistant *Acinetobacter baumannii*, and carbapenem-resistant *Escherichia coli*. The novel targeting strategy provided by this invention not only effectively overcomes the clinical bottleneck of "no available drugs" for carbapenem-resistant multidrug-resistant bacteria but also constructs a broad-spectrum protective barrier covering the entire homologous protein family, possessing extremely high clinical translational value and commercial development potential.

The application discloses an antibody, a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenamase, can reduce the carbapenam antibiotic resistance level of acinetobacter baumannii, thereby reducing the use concentration of meropenem in clinic, and improving the treatment effect of meropenem on acinetobacter baumannii. In addition, the antibody can also inhibit the OXA-23 protein secreted by bacteria, prevent the hydrolysis of carbapenam antibiotics by bacteria, increase the antibiotic concentration at a drug application site, and is favorable for clearing mixed infections with acinetobacter baumannii. The application provides a new strategy for treating acinetobacter baumannii infections, and has a wide application prospect.

The present application belongs to the technical field of complex enzyme. The present application provides a beta-lactamase complex enzyme capable of degrading various antibiotics, and a fixing method and application thereof. The preparation method of the complex enzyme comprises the following steps: extracting gene fragments of CTX-M type broad-spectrum beta-lactamase and VIM type metal-beta-lactamase from Klebsiella pneumoniae; obtaining the target gene fragments through PCR amplification, and constructing into a basic vector to obtain a recombinant vector; transforming the recombinant vector into host cells for heterologous expression; and through protein induction, SDS-PAGE protein gel electrophoresis and protein purification, the complex enzyme is obtained. The complex enzyme successfully degrades penicillins such as ampicillin, carbapenems such as imipenem, cephalosporins such as cefotaxime and other beta-lactams. The complex enzyme gene is successfully expressed in Escherichia coli, and the optimal fixing condition is obtained. The beta-lactamase complex enzyme is fixed under the optimal fixing condition, and can be repeatedly used.

The invention discloses a Ts-ELP temperature-sensitive self-assembly nano fusion protein, an antibiotic delivery system and a preparation method, and belongs to the technical field of nano preparations. The fusion protein comprises antibacterial peptide Ts and elastin-like polypeptide ELP which are sequentially connected. An MMP-9 restriction enzyme cutting site is introduced between the antibacterial peptide Ts and the elastin-like polypeptide ELP. Fusion protein and tigecycline (Tig) are self-assembled to form an antibiotic delivery system, the delivery system has Gram-negative bacterium surface lipopolysaccharide targeted recognition capability, and drug release is triggered through pH response and a phase separation mechanism in an infection microenvironment, so that the enrichment efficiency of tigecycline in a focus area is enhanced, and the drug delivery efficiency is improved. The antibiotic delivery system has the technical advantages of strong targeting property, enhanced antibacterial activity, low drug-resistant induction risk, good biological safety, simple preparation process, high yield and the like, can be used for treatment of multi-drug-resistant bacterium infection, and is especially suitable for prevention and treatment of carbapenem-resistant klebsiella pneumoniae (CRKP) and drug-resistant gram-negative bacterium infection related diseases.

The invention belongs to the technical field of biology, and relates to application of a composition of caerin1.1 / 1.9, caerin1.1 / 1.9 and polymyxin B in treatment of drug-resistant acinetobacter baumannii infection. In the caerin1.1 / 1.9, the mass ratio of the caerin1.1 to the caerin1.9 is 1 to (1 to 3). In the composition, the mass ratio of the caerin1.1 / 1.9 to the polymyxin B is 1: (0.2-3). The amino acid sequences of the caerin1.9 of the caerin1.1 are as shown in SEQ ID No. 1 and SEQ ID No. 2 of the caerin1.1. The composition of the caerin1.1 / 1.9, the caerin1.1 / 1.9 and the polymyxin B plays a role in resisting carbapenem acinetobacter baumannii by reducing the biological membrane of the acinetobacter baumannii, down-regulating the expression of efflux pump genes adeA, adeB and adeC or increasing the pore number of a cell membrane.

The application discloses application of monoterpene phenolic compounds in preparation of drug-resistant plasmid conjugative transfer inhibitors, belongs to the technical field of biological medicine, and the monoterpene phenolic compounds are carvacrol and / or thymol; the drug-resistant plasmid includes carbapenem drug-resistant plasmid. The application provides application of carvacrol and thymol in preparation of medicines for inhibiting conjugative transfer of carbapenem drug-resistant plasmid in bacteria species and between species. Experiments show that carvacrol and thymol significantly inhibit the conjugative transfer of the commonly seen carbapenem drug-resistant gene bla NDM The conjugative transfer of positive IncX3 type drug-resistant plasmid to animal source and human source strains in species and between species is proved, so that it is proved that carvacrol and thymol can be used as inhibitors of conjugative transfer of drug-resistant plasmid, so as to reduce the spread of the level of carbapenem drug resistance in feed, drinking water and organisms and even in wound infection. The inhibitor can replace antibiotics and has important popularization and application value.